DDInter601 DDInter1607
Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. Due to its evidence as an appetite stimulant and an anti-nauseant, Dronabinol is approved for use in anorexia associated with weight loss in patients with AIDS and for the treatment of nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the two most abundant cannabinoids found naturally in
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and 4 treatment-naïve patients with or without cirrhosis. Ritonavir is found in a fixed-dose combination product with , , and as the FDA-approved product Viekira Pak. First approved in December 2014, Viekira Pak is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. Ritonavir is also available as a fixed-dose combination product with and as the FDA- and Health Canada-approved product Technivie. First approved in July 2015, Technivie is indicated in combination with Ribavirin for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. In Canada, ritonavir is also available as a fixed-dose combination product with , , and as the Health Canada-approved, commercially available product Holkira Pak. First approved in January 2015, Holkira Pak is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with Ribavirin for the treatment of HCV genotype 1a with or without cirrhosis. The inclusion of ritonavir can select for HIV-1 protease inhibitor resistance-associated substitutions. Any HCV/HIV-1 co-infected patients treated with ritonavir-containing combination therapies should also be on a suppressive antiretroviral drug regimen to reduce the risk of HIV-1 protease inhibitor drug resistance. Ritonavir is combined with other drugs to treat coronavirus disease 2019 (COVID-19) in patients at risk for progressing into a severe form of the disease, such as [nirmatrelvir].
Dronabinol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ritonavir
Dronabinol {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Dronabinol {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Dronabinol {u} (Compound) binds {v} (Gene) ABCG2
ABCG2 {u} (Gene) regulates {v} (Gene) AGR2
AGR2 {u} (Gene) is upregulated by {v} (Compound) Ritonavir
Dronabinol {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Lopinavir
Lopinavir {u} (Compound) resembles {v} (Compound) Ritonavir
Dronabinol {u} (Compound) causes {v} (Side Effect) Palpitations
Palpitations {u} (Side Effect) is caused by {v} (Compound) Atazanavir
Atazanavir {u} (Compound) resembles {v} (Compound) Ritonavir
Dronabinol {u} (Compound) resembles {v} (Compound) Nabilone
Nabilone {u} (Compound) causes {v} (Side Effect) Loss of consciousness
Loss of consciousness {u} (Side Effect) is caused by {v} (Compound) Ritonavir
Dronabinol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delavirdine
Delavirdine {u} (Compound) treats {v} (Disease) acquired immunodeficiency syndrome
acquired immunodeficiency syndrome {u} (Disease) is treated by {v} (Compound) Ritonavir
Dronabinol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Modafinil {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Ritonavir
Dronabinol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Clemastine
Clemastine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ritonavir
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ritonavir (Compound)
Dronabinol (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ritonavir (Compound)
Dronabinol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound) and Atazanavir (Compound) resembles Ritonavir (Compound)
Dronabinol (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) regulates AGR2 (Gene) and AGR2 (Gene) is upregulated by Ritonavir (Compound)
Dronabinol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Lopinavir (Compound) and Lopinavir (Compound) resembles Ritonavir (Compound)
Dronabinol (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Atazanavir (Compound) and Atazanavir (Compound) resembles Ritonavir (Compound)
Dronabinol (Compound) resembles Nabilone (Compound) and Nabilone (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Ritonavir (Compound)
Dronabinol may cause a minor interaction that can limit clinical effects when taken with Delavirdine and Delavirdine (Compound) treats acquired immunodeficiency syndrome (Disease) and acquired immunodeficiency syndrome (Disease) is treated by Ritonavir (Compound)
Dronabinol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Ritonavir (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ritonavir (Compound)